This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/99919/

This is the author’s version of a work that was submitted to / accepted for publication.

Citation for final published version:

Witt, Stephanie H, Streit, Fabian, Jungkunz, Martin, Frank, Josef, Awasthi, Swapnil, Reinbold, Céline S, Treutlein, Jens, Degenhardt, Franziska, Forstner, Andreas J, Heilmann-Heimbach, Stefanie, Dietl, Lydie, Schwarze, Cornelia E, Schende, Darja I, Strohmaier, Jana, Bethell, Andrew, Craddock, Nicholas, Di Florio, Arianna, Forty, Elizabeth, Fraser, Christine, Hamshere, Marian L., Holmans, Peter, Jones, Ian, Kirov, George, O'Donovan, Michael C and Owen, Michael J 2017. Genome-wide association study of borderline personality disorder reveals genetic overlap with the bipolar disorder, schizophrenia and major depression. Translational Psychiatry 7 , e1155. file

Publishers page: http://dx.doi.org/10.1038/tp.2017.115 <http://dx.doi.org/10.1038/tp.2017.115>

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Genome-wide association study of Borderline Personality Disorder reveals genetic overlap with Bipolar Disorder, Major Depression and Schizophrenia

Psychiatric Genomics Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium, André Tadic¹¹⁷,¹¹⁸, Norbert Dahmen¹¹⁸, Björn H Schott⁴,¹¹⁹, Sven Cichon⁶,⁹¹,¹²⁰, Markus M Nöthen⁶,⁷, Stephan Ripke⁴,¹²¹,¹²², Arian Mobascher¹¹⁸, Dan Rujescu⁵⁵, Klaus Lieb¹¹⁸, Stefan Roepke⁹, Christian Schmahl², Martin Bohus³, Marcella Rietschel¹

¹ Central Institute of Mental Health, Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
² Central Institute of Mental Health, Clinic of Psychosomatic and Psychotherapeutic Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
³ Central Institute of Mental Health, Institute for Psychiatric and Psychosomatic Psychotherapy (IPPP) / Psychosomatic Medicine and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
⁴ Charité Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Mitte, Berlin, Germany
⁵ University of Basel, Human Genomics Research Group, Department of Biomedicine, Basel, Switzerland
⁶ University of Bonn, Institute of Human Genetics, Bonn, Germany
⁷ University of Bonn, Life&Brain Center, Department of Genomics, Bonn, Germany
⁸ University of Basel, Department of Psychiatry (UPK), Basel, Switzerland
⁹ Charité-Universitätsmedizin Berlin, Department of Psychiatry, Campus Benjamin Franklin, Berlin, Germany
¹⁰ University of Heidelberg, Department of Clinical Psychology and Psychotherapy, Heidelberg, Germany
¹¹ Vrije Universiteit Amsterdam, Department of Biological Psychology, Amsterdam, The Netherlands
¹² Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden
¹³ University of Adelaide, Discipline of Psychiatry, Adelaide, SA, Australia
¹⁴ Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA
¹⁵ Dalhousie University, Department of Psychiatry, Halifax, Nova Scotia, Canada
¹⁶ University of Chicago, Department of Psychiatry and Behavioral Neuroscience, Chicago, IL, USA
¹⁷ Oslo University Hospital, Division Mental Health and Addiction, Oslo, Norway
¹⁸ University of Oslo, NORMENT, Oslo, Norway
¹⁹ Russian State Medical University, Moscow, Russian Federation
²⁰ UCL London, Division of Psychiatry, London, United Kingdom
²¹ University Hospital Carl Gustav Carus, Department of Psychiatry and Psychotherapy, Dresden, Germany
²² Inserm, U1144, AP-HP, GH Saint-Louis, Département de Psychiatrie et de Médecine Addictologique, Paris, France
²³ Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden
²⁴ Cardiff University, National Center for Mental Health, Cardiff, United Kingdom
²⁵ Mayo Clinic, Health Sciences Research, Rochester, MN, USA
²⁶ University of Edinburgh, Division of Psychiatry, Edinburgh, United Kingdom
²⁷ University Medical Center Utrecht, Utrecht, The Netherlands
²⁸ Aarhus University, Department of Biomedicine, Aarhus, Denmark
Aarhus University, iSEQ, Centre for Integrative Sequencing, Aarhus, Denmark
iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark
Clinics of Upper Bavaria, Medical and Quality Assurance, Munich, Germany
International Agency for Research on Cancer, Genetic Epidemiology Group, Lyon, France
University Medical Center Göttingen, Department of Psychiatry and Psychotherapy, Goettingen, Germany
Medical Center of the University of Munich, Campus Innenstadt, Institute of Psychiatric Phenomics and Genomics (IPPG), Munich, Germany
Aarhus University, Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus, Denmark
The University of Queensland, Queensland Brain Institute, Brisbane, QLD, Australia
McGill University, Department of Psychiatry, Montreal, QC, Canada
Cardiff University, Division of Psychological Medicine and Clinical Neurosciences, Cardiff, United Kingdom
Max Planck Institute of Psychiatry, Department of Translational Research in Psychiatry, Munich, Germany
Queen Mary University of London, Centre for Psychiatry, London, United Kingdom
University College London, UCL Genetics Institute, London, United Kingdom
Poznan University of Medical Sciences, Department of Psychiatry, Laboratory of Psychiatric Genetics, Poznan, Poland
University of Marburg, Department of Psychiatry, Marburg, DE
University of Münster, Department of Psychiatry, Münster, Germany
Cardiff University, Division of Psychological Medicine and Clinical Neurosciences, Cardiff, United Kingdom
Oslo University Hospital Ullevål, Department of Medical Genetics, Oslo, Norway
University of Bergen, NORMENT, KG Jebsen Centre for Psychosis Research, Department of Clinical Science, Bergen, Norway
Università degli Studi di Trento, Centre for Integrative Biology, Trento, Italy
Indiana University School of Medicine, Biochemistry and Molecular Biology, Indianapolis, IN, USA
Indiana University School of Medicine, Medical and Molecular Genetics, Indianapolis, IN, USA
Université Paris Est, Faculté de Médecine, Créteil, France
Mayo Clinic, Department of Psychiatry & Psychology, Rochester, MN, USA
School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
Neuroscience Research Australia, Sydney, NSW, Australia
University of Halle, Department of Psychiatry, Halle, Germany
QIMR Berghofer Medical Research Institute, Genetics and Computational Biology, Brisbane, QLD, Australia
University of Worcester, Department of Psychological Medicine, Worcester, United Kingdom
University Medicine Greifswald, Department of Psychiatry and Psychotherapy, Greifswald, Germany
Plymouth University Peninsula Schools of Medicine and Dentistry, School of Biomedical and Healthcare Sciences, Plymouth, United Kingdom
University of California San Diego, Department of Psychiatry, La Jolla, CA, USA
Alexandru Obregia Clinical Psychiatric Hospital, Biometric Psychiatric Genetics Research Unit, Bucharest, Romania
University Regional Hospital, Biomedicine Institute, Mental Health Department, Málaga, Spain
Newcastle University, Institute of Genetic Medicine, Newcastle upon Tyne, United Kingdom
Eberhard Karls Universität Tübingen, Psychology, Tubingen, Germany
Inserm U955, Psychiatrie Translationnelle, Créteil, France
University Medical Center Utrecht, Division of Neuroscience, Dept. of Psychiatry, Utrecht, The Netherlands
Center of Psychiatry Weinsberg, Weinsberg, Germany
University Hospital Frankfurt am Main, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt am Main, Germany
Centre for Addiction and Mental Health, Toronto, ON, Canada
University of Toronto, Department of Psychiatry, Toronto, ON, Canada
Max Planck Institute of Psychiatry, Munich, Germany
Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain
University of Gothenburg, Institute of Neuroscience and Physiology, Gothenburg, Sweden
University Hospital Cologne, Clinic for Psychiatry and Psychotherapy, Cologne, Germany
Université Paris Est, AP-HP, DHU PePSY, Department of Psychiatry, Inserm U955, Translational Psychiatry Laboratory, Créteil, France
Janssen Research and Development, LLC, Neuroscience Therapeutic Area, Titusville, NJ, USA
M. Sklodowska-Curie Cancer Center and Institute of Oncology, Cancer Epidemiology and Prevention, Warsaw, Spain
The University of Queensland, School of Psychology, Brisbane, QLD, Australia
Lindner Center of HOPE, Research Institute, Mason, Ohio, USA
University of Edinburgh, Centre for Cognitive Ageing and Cognitive Epidemiology, Edinburgh, United Kingdom
International Agency for Research on Cancer, Genetic Cancer Susceptibility Group, Lyon, France
University College London, Division of Psychiatry, London, United Kingdom
VU University Medical Center and GGZ inGeest, Department of Psychiatry, Amsterdam, The Netherlands
School of Psychiatry, University of New South Wales, Sydney, NSW, Australia
Black Dog Institute, Sydney, NSW, Australia
University of Queensland, Institute for Molecular Biology, Brisbane, QLD, Australia
Norwegian University of Science and Technology, Neuroscience, Trondheim, Norway
St Olav's University Hospital, Psychiatry, Trondheim, Norway
Aarhus University Hospital, Risskov, Psychosis Research Unit, Aarhus, Denmark
iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus University Department of Clinical Medicine, Aarhus, Denmark
Research Center Juelich, Institute of Neuroscience and Medicine (INM-1), Juelich, Germany
University of Basel, Division of Medical Genetics, Basel, Switzerland
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
University of Liverpool, Liverpool, United Kingdom
Indiana University School of Medicine, Psychiatry, Indianapolis, IN, USA
Cardiff University, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff, United Kingdom
University of California Los Angeles, Center for Neurobehavioral Genetics, Los Angeles, CA, USA
University Medical Center Utrecht, Division of Brain Research, Utrecht, The Netherlands
Psychiatry Clinic, Clinical Center University of Sarajevo, Sarajevo, Bosnia-Herzegovina
Pfizer Global Research and Development, Human Genetics and Computational Biomedicine, Groton, CT, USA
University of Iowa, Psychiatry, Iowa City, IA, USA
Department of Psychiatry, Psychiatric University Hospital of Lausanne, Lausanne, Switzerland
McGill University, Faculty of Medicine, Department of Neurology and Neurosurgery, Montreal, QC, Canada
Montreal Neurological Institute and Hospital, Montreal, QC, Canada
Johns Hopkins University, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, USA
NIMH Division of Intramural Research Programs, Human Genetics Branch, Bethesda, MD, USA
Center for Statistical Genetics and Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
Psychiatric Center Nordbaden, Wiesloch, Germany
James Cook University, School of Medicine and Dentistry, Townsville, QLD, Australia
Broad Institute of MIT and Harvard, Medical and Population Genetics, Cambridge, MA, USA
Icahn School of Medicine at Mount Sinai, Division of Psychiatric Genomics, New York, NY, USA
Centre for Addiction and Mental Health, Molecular Neuropsychiatry and Development Laboratory, Toronto, ON, Canada
University Medicine Mannheim, Anaesthesia and Intensive Care, Mannheim, Germany
The University of Queensland, Institute for Molecular Bioscience, Brisbane, QLD, Australia
Pfizer Global Research and Development, Computational Sciences Center of Emphasis, Cambridge, MA, USA
AGAPLESION Elisabethenstift gGmbH, Department of Psychiatry, Psychosomatics and Psychotherapy, Darmstadt, DE
University Medical Center, Department of Psychiatry and Psychotherapy, Mainz, Germany
Leibniz Institute for Neurobiology, Magdeburg, Germany
University of Basel, Department of Biomedicine, Basel, Switzerland
Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research and Medical and Population Genetics Program, Cambridge, MA, USA
Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Analytic and Translational Genetics Unit, Boston, MA, USA

*These authors contributed equally
#Corresponding author
Running Title: Genome-wide association study of Borderline Personality Disorder reveals genetic overlap with the Bipolar Disorder, Major Depression and Schizophrenia
Conflicts of Interest and Sources of Funding:

The study was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Programme (grant 01ZX1314A to M.M.N. and S.C.; grant 01ZX1314G to M.R.). The study was supported by the German Research Foundation (DFG; grant FOR2107; RI908/11-1 to M.R.; WI3429/3-1 to S.W.; NO246/10-1 to M.M.N.; DA1151/5-1 to U.D., KFO 256 BO 1487/12-1 to M.B.; SFB 779 TP A08 to B.H.S.). John I Nurnberger Jr is an investigator for Assurex and a consultant for Janssen. André Tadic has received consultancy fees from Janssen and Novartis. The remaining authors reported no conflicts of interest.

Acknowledgements

The authors thank all patients and control subjects for their participation. We thank the KFO 256 workgroup of the CIMH, and Bipolar Disorder Working Group-, the Major Depression Working Group-, and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC-BIP, PGC-MDD, PGC-SCZ) for providing access to the relevant data. The Romanian sample was funded by UEFISCDI, Romania, grant no. 89/2012 to MGS. The CoLaus|PsyCoLaus study was and is supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, and the Swiss National Science Foundation (grants 3200B0–105993, 3200B0-118308, 33CSCO-122661, 33CS30-139468 and 33CS30-148401).
Abstract

Borderline personality disorder (BOR) is determined by environmental and genetic factors, and characterized by affective instability and impulsivity, diagnostic symptoms also observed in manic phases of Bipolar Disorder (BIP). Up to 20% of BIP patients show comorbidity with BOR. This report describes the first case-control genome-wide association study (GWAS) of BOR, performed in one of the largest BOR patient samples worldwide. The focus of our analysis was: (i) to detect genes and gene-sets involved in BOR; and (ii) to investigate the genetic overlap with BIP. As there is considerable genetic overlap between BIP, Major Depression (MDD) and Schizophrenia (SCZ) and a high comorbidity of BOR and MDD, we also analyzed the genetic overlap of BOR with SCZ and MDD. GWAS, gene-based tests, and gene-set-analyses were performed in 998 BOR patients and 1,545 controls. LD score regression was used to detect genetic overlap between BOR and these disorders. Single marker analysis revealed no significant association after correction for multiple testing. Gene-based analysis yielded two significant genes: DPYD (p=4.42x10^{-7}) and PKP4 (p=8.67x10^{-7}); and gene-set-analysis yielded a significant finding for exocytosis (GO:0006887, p_{FDR}=0.019).

Prior studies have implicated DPYD, PKP4 and exocytosis in BIP and SCZ. The most notable finding of the present study was the genetic overlap of BOR with BIP (r_g=0.28 [p=2.99x10^{-3}]), SCZ (r_g=0.34 [p=4.37x10^{-5}]), and MDD (r_g=0.57 [p=1.04x10^{-3}]). Our study is the first to demonstrate that BOR overlaps with BIP, MDD and SCZ on the genetic level. Whether this is confined to transdiagnostic clinical symptoms should be examined in future studies.
Introduction

Borderline Personality Disorder (BOR\textsuperscript{1}) is a complex neuropsychiatric disorder with a lifetime prevalence of around 3\% (1). Untreated cases often have a chronic and severely debilitating clinical course (1). BOR affects up to 20\% of all psychiatric inpatients, and is associated with high healthcare utilization. BOR therefore represents a substantial socio-economic burden (2, (3).

BOR is characterized by affective instability, emotional dysregulation, and poor interpersonal functioning (3). Suicide rates in BOR range between 6\% and 8\%, and up to 90\% of patients engage in non-suicidal self-injurious behavior (4). Other prototypical features include high-risk behaviors and impulsive aggression. Current theories view dysfunctions in emotion processing, social interaction, and impulsivity as core psychological mechanisms of BOR (5).

To date, genetic research into BOR has been limited. Available genetic studies have involved small samples and focused on candidate genes, while no genome-wide association study (GWAS) of BOR patients has yet been performed (6). However, Lubke et al. (2014) conducted a GWAS of borderline personality features using data from three cohorts comprising n=5,802, n=1,332 and n=1,301 participants, respectively (7). Using the borderline subscale of the Personality Assessment Inventory (PAI-BOR), four Borderline personality features (affect instability, identity problems, negative relations, and self-harm) were assessed. The most promising signal in the combined analysis of two samples was for seven SNPs in the gene \textit{SERINC5}, which encodes a protein involved in myelination. Two of the SNPs could be replicated in the third sample. Interestingly, here, the effect was highest for the affect instability items, i.e., features that are key characteristics of manic phases of Bipolar Disorder (BIP).

Understanding of the pathogenesis of BOR remains limited. Both environmental and genetic factors are known to play a role in BOR etiology. Familial aggregation has been demonstrated (8, (9), and heritability estimates from twin studies range from 35\% to 65\%, with higher heritability estimates being obtained with self-ratings (10, (11, (12).

\textsuperscript{1} For the sake of readability, we have decided to use the rather unconventional abbreviation “BOR” for Borderline Personality Disorder and the abbreviation “BIP” for Bipolar Disorder.
The potential comorbidity between BOR and BIP is part of an ongoing debate. For example, Fornaro et al. (2016) report substantial comorbidity of ~20% with BIP (13), whereas Tsansas et al. (2016) find clear symptomatic differences between these two diagnostic groups. BOR displays an overlap of some symptoms with BIP, such as affective instability (14). In contrast, features such as dissociative symptoms, a feeling of chronic emptiness, and identity disturbances are specific to BOR (15). To date, no twin or family study has generated conclusive results concerning a genetic overlap between the two disorders (16, 17). However, a twin study (18) and a large population based study using polygenic risk score analyses (19) indicate a genetic overlap between Borderline personality features and neuroticism, an established risk factor for BIP and other psychiatric disorders (20).

The present study represents the first case-control GWAS in BOR, and was performed in one of the largest BOR patient samples worldwide. Given the limited heritability and the expected complex genetic architecture of BOR, the sample is too small to generate significant results for single markers. Instead, the main aim of the investigation was to detect: (i) genes and gene-sets with a potential involvement in BOR; and (ii) potential genetic overlap with BIP. As a substantial overlap of common risk variants exists between BIP and Schizophrenia (SCZ), and to a lesser extent between BIP and Major Depressive Disorder (MDD), and as there is also a high comorbidity of BOR and MDD, a further aim of the study was to determine whether any observed genetic overlap between BOR and BIP, MDD and SCZ was driven by disorder-specific genetic factors using LD-score regression and polygenic risk scores (PRS).

Materials and Methods

Participants

The present sample comprised 1,075 BOR patients and 1,675 controls (21). All participants provided written informed consent prior to inclusion. The study was approved by the respective local ethics committees.
Patients were recruited at the following German academic institutions: Department of Psychosomatic Medicine, Central Institute of Mental Health, Mannheim (n=350); Department of Psychiatry and Psychotherapy, University Medical Center Mainz (n=231); and the Department of Psychiatry, Charité, Campus Benjamin Franklin, Berlin (n=494). Inclusion criteria for patients were: age 16 to 65 years; Central European ancestry; and a lifetime DSM-IV diagnosis of BOR. The control sample comprised 1,583 unscreened blood donors from Mannheim, and 92 subjects recruited by the University Medical Center Mainz.

**Clinical assessment**

Diagnoses of BOR were assigned according to DSM-IV criteria and on the basis of structured clinical interviews. The diagnostic criteria for BOR were assessed using the German version of the IPDE (22) or the SKID-II (23). All diagnostic interviews were conducted by trained and experienced raters. BOR patients with a comorbid diagnosis of BIP or SCZ assessed with SKID-I (23) were excluded.

**Genotyping**

Automated genomic DNA extraction was performed using the chemagic Magnetic Separation Module I (Chemagen Biopolymer-Technologie AG; Baesweiler; Germany). Genotyping was performed using the Infinium PsychArray-24 Bead Chip (Illumina, San Diego, USA).

**Quality control and Imputation**

A detailed description of the quality control and imputation procedures is provided elsewhere (24).

Briefly, quality control parameters for the exclusion of subjects and single nucleotide polymorphisms (SNPs) were: subject missingness>0.02; autosomal heterozygosity deviation (|Fhet|>0.2); SNP missingness>0.02; difference in SNP missingness between cases and controls>0.02; and SNP Hardy-Weinberg equilibrium (p<10⁻⁶ in controls; p<10⁻¹⁰ in cases).
Genotype imputation was performed using the pre-phasing/imputation stepwise approach in IMPUTE2/SHAPEIT (default parameters and a chunk size of 3 Mb) (25, (26), using the 1000 Genomes Project reference panel (release “v3.macGT1”) (27).

Relatedness testing and population structure analysis were performed using a SNP subset that fulfilled strict quality criteria (INFO>0.8, missingness<1%, minor allele frequency (MAF)>0.05), and which had been subjected to linkage disequilibrium (LD) pruning ($r^2$>0.02). This subset comprised 63,854 SNPs. In cryptically related subjects, one member of each pair ($\hat{\rho}$>0.2) was removed at random following the preferential retention of cases over controls. Principal components (PCs) were estimated from genotype data (see Supplementary Figure 1-6), and phenotype association was tested using logistic regression. The impact of the PCs on genome-wide test statistics was assessed using $\lambda$.

**Association Analysis**

Including the first four PCs as covariates, an additive logistic regression model was used to test single marker associations, as implemented in PLINK (28). The p-value threshold for genome-wide significance was set at $5 \times 10^{-8}$.

**Gene-based-analysis**

To determine whether genes harbored an excess of variants with small p-values, a gene-based test was performed with MAGMA Version 1.04 (http://ctg.cancer.nl/software/magma) (29) using genotyped markers only, filtered with a MAF>1% (n=284,220). This test uses summary data, and takes LD between variants into account. SNPs within +/-10 kb of the gene boundary were assigned to each gene. Obtained p-values were Bonferroni-corrected for the number of tested genes (n=17,755, p=2.8x10^{-6}).

**Gene-set-analysis**

Gene-set-based analysis was implemented using genotyped markers only, filtered as above. As in the gene-based-analysis, SNPs within +/-10 kb of the gene boundary were assigned to
each gene. Gene-set-analyses were carried out using Gene Ontology (GO, http://software.broadinstitute.org/gsea/msigdb/) terms.

Discovery gene-set-based-analysis was carried out using i-GSEA4GWASv2 (http://gsea4gwas-v2.psych.ac.cn/) (30). The size of the gene-sets was restricted to 20-200 genes, and the major histocompatibility complex (MHC) region was excluded. In total 674 gene-sets were tested. Results were adjusted for multiple testing using false discovery rate (FDR). To validate the significant finding, the respective gene-set was investigated with i.) GSA-SNP, using the p-value of the second-best SNP in each gene (https://gsa.muldas.org) (31), and ii.) MAGMA using summary data and a nominal p-value threshold of p<0.05.

**LD-Score Regression**

To investigate a possible genetic overlap between BOR and SCZ, BIP and MDD, LD-score regression was performed (32). Genetic correlations between BOR and (i) BIP, (ii) SCZ, and (iii) MDD were calculated (33) using the result files of the Psychiatric Genomics Consortium (PGC) metaanalyses for SCZ (33,640 cases & 43,456 controls) (34), BIP (20,352 cases & 31,358 controls) (35) and MDD (16,823 cases & 25,632 controls) (35). There was no overlap in cases or controls of the present BOR GWAS sample with the PGC samples.

**Polygenic Risk Score**

To determine the impact of polygenic risk on BOR and subgroups (i.e., BOR with and without MDD), polygenic risk scores (PRS) were calculated for each subject based on the above-mentioned PGC datasets.

To obtain a highly informative SNP set with minimal statistical noise, the following were excluded: low frequency SNPs (MAF<0.1); low-quality variants (imputation INFO<0.9) and indels. Subsequently, these SNPs were clumped discarding markers within 500 kb of, and in high LD (r²≥0.1) with, another more significant marker. From the MHC region, only one variant with the strongest significance was retained. PRS were calculated as described elsewhere (36). This involved p-value thresholds 5x10⁻⁸, 1x10⁻⁶, 1x10⁻⁴, 0.001, 0.01, 0.05,
0.1, 0.2, 0.5, and 1.0, and multiplication of the natural logarithm of the odds ratio of each variant by the imputation probability for the risk allele. The resulting values were then totaled. For each subject, this resulted in one PRS for SCZ, MDD, and BIP for each p-value threshold.

In a first step, the association of the PRS for BIP, SCZ, and MDD with BOR case control status was analyzed using standard logistic regression and by including the four PCs as covariates. For each p-value threshold, the proportion of variance explained (Nagelkerke’s R²) in BOR case-control status was computed by comparison of a full model (covariates + PRS) score to a reduced model (covariates only).

For further exploratory analysis, the p<0.05 PRS for each disorder was selected (i.e. including all markers that reached nominal significance in the training samples). To determine whether the different scores contribute independently to the case-control status, a regression including the PRS for MDD, SCZ, and BIP and the four PCs was computed. In a secondary analysis, two further models were computed. These included the PRS for BIP and the PRS of either MDD or SCZ, while controlling for the four PCs.

Furthermore, PRS were analyzed by differentiating between controls, and patients with or without comorbid MDD. For each PRS, a linear model was computed using the PRS as a dependent variable, disease state as an independent variable, and the four PCs as covariates. Differences between groups were assessed using post-hoc tests (Bonferroni-corrected).

**Results**

**Sample characteristics**

Genetic quality control led to the exclusion of 207 subjects. Reasons for exclusion were: (i) insufficient data quality (low call rate), n=6; (ii) relatedness, n= 63; and (iii) population outlier status, n= 138. After quality control, the sample comprised 998 BOR cases (914 female / 84 male) and 1,545 controls (868 female / 677 male). Mean age for cases was 29.58 years (range: 18–65 years, standard deviation (SD=8.64)). Mean age for controls was 44.19 years.
(range: 18–72 years, SD=13.24) (details see Supplementary Table 1). Of the 998 cases, 666 had co-morbid life-time MDD, and 262 did not (data missing for 40 cases).

**Single marker analysis**

A total of 1,073,631,316 single markers were included in the analysis. As expected for GWAS on a complex psychiatric disorder with the current sample size, the single marker analysis revealed no significant hit after correction for multiple testing (see Figure 1&2). The most significant marker was rs113507694 in **DPPA3** on chromosome 12 (p=2.01×10^{-7}; OR=0.35, MAF=0.03, INFO=0.59). Single markers with p<1x10^{-5} are listed in Supplementary Table 2.

**Gene-based-analysis**

In the gene-based-analysis, a total of 17,755 genes were tested. Two genes showed significant association with BOR after correction for multiple testing: the gene coding for Plakophilin-4 on chromosome 2 (**PKP4**; p=8.24×10^{-7}); and the gene coding for dihydropyrimidine dehydrogenase on chromosome 1 (**DPYD**, p=1.20×10^{-6}). The most significant genes (p<5x10^{-4}) are listed in Table 1. The top hit of the previous GWAS of Borderline personality features, **SERINC5**, achieved nominal significance in the present study (p_{uncorrected}=0.016).

**Gene-set-analysis**

Gene-set-analysis with i-GSEA4GWASv2 revealed one significant gene-set: exocytosis (GO: 0006887; p_{FDR}=0.019). Of 25 genes in this gene-set, 22 were mapped with variants and 15 showed nominally significant associations. Details on significant and non-significant genes in this gene-set are provided in Supplementary Table 3. All gene-sets with p_{uncorrected}<0.01 are shown in Table 2. A technical replication analysis with GSA-SNP and MAGMA confirmed the gene-set exocytosis (GSA-SNP: p_{uncorrected}=2.32×10^{-4}; MAGMA: p_{uncorrected} = 0.056).

**LD-Score regression**
Significant genetic correlations with BOR were found for BIP ($r_g=0.28; \text{SE}=0.094; p=2.99 \times 10^{-3}$), MDD ($r_g=0.57; \text{SE}=0.18; p=1.04 \times 10^{-3}$), and SCZ ($r_g=0.34; \text{SE}=0.082; p=4.37 \times 10^{-5}$); a meta-analytic comparison revealed no significant differences between the correlations (all $p > 0.13$).

**Polygenic Risk Score**

PRS analysis revealed significant associations with BOR for the PRS of BIP, MDD, and SCZ. SCZ PRS were significant for all investigated thresholds. BIP and MDD scores were significant for all PRS that included SNPs with p-values higher than 0.0001 and 0.001 respectively (see Supplementary Table 4). The share of variance explained in BOR case-control status (Nagelkerke’s $R^2$) by the respective PRS was up to 0.86% for BIP; up to 3.1% for SCZ; and up to 2.1% for MDD (see Figure 3 and Supplementary Table 4).

Simultaneous addition of the PRS for SCZ, BIP, and MDD (threshold $p<0.05$) to the regression model explained 4.4% of the variance (Nagelkerke’s $R^2$) in BOR case-control status. The PRS for SCZ and the PRS for MDD were significant predictors ($p=9.78 \times 10^{-9}$ and $p=1.9 \times 10^{-7}$, respectively). The PRS for BIP was not a significant predictor in this model ($p=0.28$).

A secondary analysis was then performed including: (i) BIP PRS with MDD PRS; and (ii) BIP PRS with SCZ PRS. Here, BIP PRS explained variance independently of MDD PRS ($p=0.0067$), but not of SCZ PRS ($p = 0.11$).

Differentiation between cases with and without comorbid MDD and controls revealed significant effects of BOR diagnosis on PRS for BIP, SCZ, and MDD (all $p<0.001$, see Figure 4). Post-hoc analyses revealed no differences in PRS for the BIP, SCZ, or MDD PRS of the BOR subgroup with comorbid MDD compared to the BOR subgroup without MDD (all $p>0.5$). Compared to controls, PRS for SCZ and MDD were significantly increased in the BOR subgroups with and without comorbid MDD (all $p<0.001$). The PRS for BIP only showed a
significant difference to controls in the BOR subgroup with comorbid MDD (p<0.001, see Figure 4).

Discussion

The present study is the first case-control GWAS of BOR. As expected, no genome-wide significant association was found for any single marker. In the gene-based test, however, two genes achieved genome-wide significance: Dihydropyrimidine Dehydrogenase (DPYD) and Plakophilin4 (PKP4). DPYD encodes a pyrimidine catabolic enzyme, which is the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Genetic deficiency of this enzyme results in an error in pyrimidine metabolism (37). This is associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy (http://www.ncbi.nlm.nih.gov/gene/1806). Recent Psychiatric Genomics Consortium (PGC) metaanalyses revealed an association between DPYD and SCZ and BIP (34, (38, (39). DPYD contains a binding site for the micro-RNA miR-137, which has previously been associated with schizophrenia (40), and a previous exome sequencing study reported two putative functional de novo variants in DPYD in cases with SCZ (41). PKP4 is involved in the regulation of cell adhesion and cytoskeletal organization (42). In pathway analyses of PGC GWAS data, cell adhesion was associated with BIP (43), and SCZ (44), whereas cell junction was implicated in MDD, as well as in an integrative pathway analysis of all three disorders (45).

SERINC5, which was the top hit of the previous GWAS of Borderline personality features (7), achieved nominal significance in the present study. The protein SERINC5 incorporates serine into newly forming membrane lipids, and is enriched in myelin in the brain (46). Previous research suggests that decreased myelination is associated with a reduced capacity for social interaction (7, (47).

The gene-set analyses yielded significant results for exocytosis. In neuronal synapses, exocytosis is triggered by an influx of calcium and critically underlies synaptic signaling.
Dysregulated neuronal signaling and exocytosis are core features of neurodevelopmental psychiatric disorders such as the autism spectrum disorders and intellectual disability (48, 49). Moreover, recent findings from large metaanalyses have implicated dysregulated neuronal signaling and exocytosis in the molecular mechanisms of BIP, SCZ, and MDD (48, 50, 51). These processes may now represent promising starting points for further research into BOR.

The most interesting finding of this study is that BOR showed a genetic overlap with BIP, SCZ, and MDD. Notably, BIP did not show a higher correlation with BOR ($r_g=0.28$) than SCZ ($r_g=0.34$) or MDD ($r_g=0.57$). In view of the present sample size, these values must be viewed with caution. A more accurate estimation of these correlations will require calculations in larger cohorts.

Although comorbid BIP was excluded in the present BOR patients, the possibility that the observed genetic overlap between BOR and BIP was at least partly attributable to misdiagnosis cannot be excluded. However, an alternative explanation appears more likely, i.e. that disorders currently categorized as BOR and BIP share a common genetic background, and they also do so with SCZ and MDD. This hypothesis is supported by the present observation of a genetic overlap between BOR and SCZ, two disorders that are rarely misdiagnosed by psychiatrists, despite the presence of common psychotic symptoms.

An explanation could also be that the genetic commonality between BOR and BIP, SCZ, and MDD might be due to a common effect of MDD. Prior to the introduction of DSM-IV, a history of MDD was required for a diagnosis of BIP, and MDD has a high prevalence in patients with SCZ (25-85%) (52, 53). Therefore, the MDD genetic risk variants that are common to BOR, BIP, and SCZ may be responsible for the observed overlap. For this reason, we conducted two further analyses. First, we compared PRS of BIP, SCZ, and MDD in subsamples of BOR patients with (~60%) and without comorbid MDD. Here, no differences in any of the PRS were found. Second, we performed a joint analysis of PRS of BIP, SCZ, and MDD in a logistic regression analysis in BOR patients vs. controls. Here, no differences were found in any of the PRS. Second, we performed a joint analysis of the PRS of BIP, SCZ, and MDD in
a logistic regression analysis in BOR patients vs. controls. Here, both the SCZ and the MDD risk score explained variance in BOR case-control status independently. Secondary analysis revealed that the BIP risk score explained variance independently of the MDD risk score but not of the SCZ risk score. These results indicate that comorbidity with MDD does not explain the genetic overlap between BOR and BIP, SCZ, and MDD. However, the training sets differ in terms of their power to detect underlying risk variants, and therefore the derived PRS differ in terms of the variance they can explain.

It must be noted, that in the PGC-BIP, -SCZ and -MDD samples, controls are partly overlapping. However, it is unlikely that this drives the genetic correlation of BOR with those disorders as the overlap of controls in these samples is rather small (under 10%) (54). Also, the joint logistic regression analysis demonstrated that polygenic risk for SCZ and MDD contributed independently to the BOR risk (see above).

The present study had several limitations. First, despite being one of the largest BOR samples available worldwide, the sample size was small in terms of the estimation of heritability. Replication of the present results is warranted in larger, independent cohorts. This should include the investigation of non-European samples. Second, no information was available on the presence of common clinical features such as psychotic symptoms and affect instability. This precluded detailed analysis of the identified genetic overlap. Future studies in larger cohorts should also investigate more detailed phenotypes, including comorbid axis I and axis II disorders, such as addiction and personality disorders, respectively. Third, the observation that psychiatric patients often establish non-random relationships with persons affected by the same or another psychiatric disorder (55), and therefore have offspring with a higher genetic risk for psychiatric disorders, might contribute to the observed genetic correlation of BOR with BIP, SCZ, and MDD. However, the LD score method does not investigate the impact of assortative mating (32). Therefore, assessment of the degree to which this phenomenon may have influenced the genetic correlation estimates was beyond the scope of the present study."
Despite these limitations, the results indicate that neither comorbidity with MDD nor risk variants that are exclusive to MDD explain the genetic overlap between BOR and BIP, SCZ, and MDD. Future investigations of larger data sets for BOR and other psychiatric disorders are warranted to refine the analysis of shared and specific genetic risk.

Future studies are warranted to delineate the communalities and specificities of the respective disorders.

**Conclusion**

In summary, the present study is the first GWAS of patients diagnosed with BOR. The results suggest promising novel genes and a novel pathway for BOR, and demonstrate that, rather than being a discrete entity, BOR has an etiological overlap with the major psychoses. The genetic overlap with BIP is consistent with the observation that some diagnostic criteria for BOR overlap with those for BIP. The overlap between BOR and SCZ and MDD is consistent with previous observations of genetic overlap of other psychiatric disorders (56). Given that BOR patients display specific clinical symptoms not observed in patients with other psychiatric disorders, knowledge of shared and non-shared genetic and clinical features will be important for the development of personalized treatment approaches.

Supplementary information is available at *Translational Psychiatry*’s website.
References


Figure Legends

**Figure 1: Quantile-Quantile plot.** Quantile-Quantile plot of the case-control analysis (998 cases; 1,545 controls) showing expected and observed $-\log_{10}$ p-values. The shaded region indicates the 95% confidence interval of expected p-values under the null hypothesis.

**Figure 2: Manhattan plot showing association results.** Manhattan plot of the case-control analysis (998 cases; 1,545 controls). For each SNP, the chromosomal position is shown on the x-axis, and the $-\log_{10}$ p-value on the y-axis. The red line indicates genome-wide significance ($p<5\times10^{-8}$) and the blue line indicates suggestive evidence for association ($p<1\times10^{-5}$).

**Figure 3: Polygenic Risk Score analysis.** The proportion of variance explained in case-control status (y axis; Nagelkerke’s $R^2$) by the PRS for BIP, SCZ, and MDD is depicted for the different p-value cutoffs used in the calculation of the PRS. Principal components were included in the models to control for population stratification. PRS = Polygenic risk score; BIP = Bipolar Disorder; MDD = Major Depressive Disorder; SCZ = Schizophrenia; ns = non-significant; 1* $p<0.05$; 2* $p<0.001$; 3* $p<1\times10^{-4}$; 4* $p<1\times10^{-6}$; 5* $p<1\times10^{-8}$; 6* $p<1\times10^{-10}$; 7* $p<1\times10^{-12}$

**Figure 4: Polygenic Risk Score analysis in subgroups.** Mean z-standardized PRS and standard error (SE) for BIP, SCZ, and MDD are shown in the control group, all cases, and in cases with and without comorbid MDD. PRS with a p-value threshold of $p=0.05$ were selected for this comparison and principal components were included in the models to control for population stratification. The numbers at the top of each bar indicate the significance of the difference in the respective PRS in comparison to the control group. BOR = Borderline Personality Disorder; BIP = Bipolar Disorder; MDD = Major Depressive Disorder; SCZ = Schizophrenia; ns = non-significant; 1* $p<0.05$; 2* $p<0.001$; 3* $p<1\times10^{-4}$; 4* $p<1\times10^{-6}$; 5* $p<1\times10^{-8}$; 6* $p<1\times10^{-10}$; 7* $p<1\times10^{-12}$
lambda1 = 1.030, N (p-value) = 8714176
lambda1000 = 1.625 (598 cases, 1540 controls)
Supplementary Information for Genome-wide association study of Borderline Personality Disorder reveals genetic overlap with the Major Psychoses

Table of Content

Figures......................................................................................................................................... 2
Supplementary Figure 1: Scatter plot of principal components 1 and 2................................. 2
Supplementary Figure 2: Scatter plot of principal components 1 and 3................................. 2
Supplementary Figure 3: Scatter plot of principal components 2 and 3................................. 3
Supplementary Figure 4: Scatter plot of principal components 2 and 4................................. 3
Supplementary Figure 5: Scatter plot of principal components 3 and 4................................. 4
Supplementary Figure 6: Scatter plot of principal components 5 and 6................................. 4
Supplementary Figure 7: Region plot of PKP4....................................................................... 5
Supplementary Figure 8: Region plot of DPYD....................................................................... 5

Tables..........................................................................................................................................6
Supplementary Table 1: Demographic and clinical information on the final sample........... 6
Supplementary Table 2: Association results for single markers............................................. 7
Supplementary Table 3: Overview of Gene Set Excytosis (GO: 0006887)............................ 13
Supplementary Table 4: Association of polygenic risk scores for Bipolar Disorder (BIP), Schizophrenia (SCZ), and Major Depressive Disorder (MDD) with Borderline Personality Disorder case control status.......................................................... 14

Consortium Memberships......................................................................................................... 15
Bipolar Disorders Working Group of the Psychiatric Genomics Consortium (Bipolar disorder)................................................................................................................................ 15
Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (Major depressive disorder)................................................................................................. 16
Figures

Supplementary Figure 1: Scatter plot of principal components 1 and 2

Supplementary Figure 2: Scatter plot of principal components 1 and 3
Supplementary Figure 3: Scatter plot of principal components 2 and 3

Supplementary Figure 4: Scatter plot of principal components 2 and 4

Supplementary Figure 5: Scatter plot of principal components 3 and 4
Supplementary Figure 6: Scatter plot of principal components 5 and 6
## Tables

**Supplementary Table 1: Demographic and clinical information on the final sample**

<table>
<thead>
<tr>
<th></th>
<th>Cases</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>998</td>
<td>1,545</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>914 / 84</td>
<td>868 / 677</td>
</tr>
<tr>
<td>Age in years (SD)</td>
<td>29.58 (8.64)</td>
<td>44.19 (13.24)</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(yes / no / missing)</td>
<td>666 / 262 / 40</td>
<td>-</td>
</tr>
<tr>
<td>Alcohol dependency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(yes / no / missing)</td>
<td>163 / 781 / 54</td>
<td>-</td>
</tr>
</tbody>
</table>
Supplementary Table 2: Association results for single markers

Markers are reported with \( p < 1 \times 10^{-5} \), and sorted according to chromosomal position. **CHR** = chromosome, **BP** = base pair position, **A** = allele, **FRQ** = frequency, **SNP** = single nucleotide polymorphism, **OR** = odds ratio, **INFO** = imputation info score, **SE** = standard error, **GT** = genotyped, **IMP** = imputed

<table>
<thead>
<tr>
<th>CHR</th>
<th>SNP</th>
<th>BP</th>
<th>Gene</th>
<th>A1</th>
<th>A2</th>
<th>FRQ cases</th>
<th>FRQ controls</th>
<th>INFO</th>
<th>OR</th>
<th>SE</th>
<th>P</th>
<th>GT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>rs187785463</td>
<td>98152125</td>
<td>DPYD</td>
<td>A</td>
<td>G</td>
<td>0.0531</td>
<td>0.0739</td>
<td>0.752</td>
<td>0.4935</td>
<td>0.1572</td>
<td>7.05E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>1</td>
<td>rs6683957</td>
<td>98200719</td>
<td>DPYD</td>
<td>A</td>
<td>G</td>
<td>0.078</td>
<td>0.1128</td>
<td>1.002</td>
<td>0.6117</td>
<td>0.111</td>
<td>9.46E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs57726666</td>
<td>16203326</td>
<td>GACAT3</td>
<td>A</td>
<td>G</td>
<td>0.9407</td>
<td>0.9125</td>
<td>0.912</td>
<td>1.8855</td>
<td>0.1341</td>
<td>2.24E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs70068563</td>
<td>16208690</td>
<td>GACAT3</td>
<td>A</td>
<td>G</td>
<td>0.9397</td>
<td>0.9127</td>
<td>0.9227</td>
<td>1.8395</td>
<td>0.1324</td>
<td>4.19E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs115689122</td>
<td>52606079</td>
<td>AC087073.1</td>
<td>A</td>
<td>T</td>
<td>0.016</td>
<td>0.0054</td>
<td>0.7809</td>
<td>6.1189</td>
<td>0.4062</td>
<td>8.20E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs62127626</td>
<td>52719291</td>
<td>AC139712.4</td>
<td>A</td>
<td>C</td>
<td>0.0163</td>
<td>0.0057</td>
<td>0.7744</td>
<td>5.9639</td>
<td>0.3984</td>
<td>7.38E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs150592717</td>
<td>89936117</td>
<td></td>
<td>T</td>
<td>C</td>
<td>0.8884</td>
<td>0.869</td>
<td>0.3247</td>
<td>2.2187</td>
<td>0.1796</td>
<td>9.14E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs4664975</td>
<td>159418438</td>
<td>PKP4</td>
<td>A</td>
<td>C</td>
<td>0.4677</td>
<td>0.5152</td>
<td>0.8943</td>
<td>0.7399</td>
<td>0.0678</td>
<td>8.77E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs3771608</td>
<td>159419739</td>
<td>PKP4</td>
<td>A</td>
<td>C</td>
<td>0.5405</td>
<td>0.4847</td>
<td>0.9831</td>
<td>1.345</td>
<td>0.0646</td>
<td>4.42E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs12052933</td>
<td>159420140</td>
<td>PKP4</td>
<td>A</td>
<td>G</td>
<td>0.54</td>
<td>0.4841</td>
<td>0.9852</td>
<td>1.3451</td>
<td>0.0645</td>
<td>4.29E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs10174340</td>
<td>159421412</td>
<td>PKP4</td>
<td>A</td>
<td>T</td>
<td>0.54</td>
<td>0.4841</td>
<td>0.9856</td>
<td>1.3451</td>
<td>0.0645</td>
<td>4.27E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs3771609</td>
<td>159422239</td>
<td>PKP4</td>
<td>T</td>
<td>C</td>
<td>0.46</td>
<td>0.516</td>
<td>0.9859</td>
<td>0.7434</td>
<td>0.0645</td>
<td>4.25E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs3771610</td>
<td>159422317</td>
<td>PKP4</td>
<td>A</td>
<td>G</td>
<td>0.54</td>
<td>0.484</td>
<td>0.9859</td>
<td>1.3451</td>
<td>0.0645</td>
<td>4.25E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs10187426</td>
<td>159425104</td>
<td>PKP4</td>
<td>A</td>
<td>G</td>
<td>0.5399</td>
<td>0.4839</td>
<td>0.9869</td>
<td>1.3451</td>
<td>0.0644</td>
<td>4.21E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs7577672</td>
<td>159429019</td>
<td>PKP4</td>
<td>A</td>
<td>G</td>
<td>0.4748</td>
<td>0.5324</td>
<td>0.9886</td>
<td>0.7523</td>
<td>0.0643</td>
<td>9.56E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs3771614</td>
<td>159430579</td>
<td>PKP4</td>
<td>T</td>
<td>G</td>
<td>0.5318</td>
<td>0.4731</td>
<td>0.9904</td>
<td>1.3443</td>
<td>0.0643</td>
<td>4.26E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs3771616</td>
<td>159430991</td>
<td>PKP4</td>
<td>A</td>
<td>G</td>
<td>0.5318</td>
<td>0.4731</td>
<td>0.9903</td>
<td>1.3444</td>
<td>0.0643</td>
<td>4.23E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>2</td>
<td>rs3821291</td>
<td>159431031</td>
<td>PKP4</td>
<td>A</td>
<td>G</td>
<td>0.5318</td>
<td>0.4731</td>
<td>0.9903</td>
<td>1.3444</td>
<td>0.0643</td>
<td>4.23E-06</td>
<td>IMP</td>
</tr>
<tr>
<td>Marker</td>
<td>Chromosome</td>
<td>Gene</td>
<td>Nucleotide</td>
<td>Distance</td>
<td>Minor Allele</td>
<td>Major Allele</td>
<td>p Value</td>
<td>Beta</td>
<td>SE</td>
<td>FDR</td>
<td>IMP</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>------</td>
<td>------------</td>
<td>----------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------</td>
<td>------</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>rs12473797</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.5319</td>
<td>0.4732</td>
<td>0.9898</td>
<td>1.3449</td>
<td>0.0644</td>
<td>4.14E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3755408</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.5318</td>
<td>0.4731</td>
<td>0.9903</td>
<td>1.3445</td>
<td>0.0643</td>
<td>4.21E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chr2_159432313_D</td>
<td>chr2</td>
<td>PKP4</td>
<td>I2 D</td>
<td>0.5496</td>
<td>0.4914</td>
<td>0.9516</td>
<td>1.3537</td>
<td>0.0658</td>
<td>4.13E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2356189</td>
<td>chr2</td>
<td>PKP4</td>
<td>A G</td>
<td>0.5402</td>
<td>0.4839</td>
<td>0.9869</td>
<td>1.3482</td>
<td>0.0644</td>
<td>3.55E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3755413</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.528</td>
<td>0.4703</td>
<td>0.9825</td>
<td>1.3387</td>
<td>0.0646</td>
<td>6.23E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chr2_159432313_D</td>
<td>chr2</td>
<td>PKP4</td>
<td>I2 D</td>
<td>0.5496</td>
<td>0.5157</td>
<td>0.9868</td>
<td>0.7414</td>
<td>0.0645</td>
<td>3.11E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs4664979</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.4597</td>
<td>0.5161</td>
<td>0.9865</td>
<td>0.741</td>
<td>0.0645</td>
<td>3.31E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3771627</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.4596</td>
<td>0.5161</td>
<td>0.9865</td>
<td>0.741</td>
<td>0.0645</td>
<td>3.31E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2108215</td>
<td>chr2</td>
<td>PKP4</td>
<td>T G</td>
<td>0.4674</td>
<td>0.5269</td>
<td>0.9909</td>
<td>0.7404</td>
<td>0.0643</td>
<td>3.01E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs11891131</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.532</td>
<td>0.4731</td>
<td>0.9898</td>
<td>1.347</td>
<td>0.0644</td>
<td>3.71E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1465236</td>
<td>chr2</td>
<td>PKP4</td>
<td>A G</td>
<td>0.4682</td>
<td>0.527</td>
<td>0.9894</td>
<td>0.7424</td>
<td>0.0644</td>
<td>3.71E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs999232</td>
<td>chr2</td>
<td>PKP4</td>
<td>C G</td>
<td>0.468</td>
<td>0.5269</td>
<td>0.9899</td>
<td>0.7422</td>
<td>0.0644</td>
<td>3.62E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3771631</td>
<td>chr2</td>
<td>PKP4</td>
<td>A C</td>
<td>0.468</td>
<td>0.5269</td>
<td>0.9898</td>
<td>0.7422</td>
<td>0.0644</td>
<td>3.62E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3771632</td>
<td>chr2</td>
<td>PKP4</td>
<td>T G</td>
<td>0.5341</td>
<td>0.4763</td>
<td>0.9806</td>
<td>1.3485</td>
<td>0.0646</td>
<td>3.75E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2051946</td>
<td>chr2</td>
<td>PKP4</td>
<td>A G</td>
<td>0.5321</td>
<td>0.4733</td>
<td>0.9884</td>
<td>1.3472</td>
<td>0.0644</td>
<td>3.71E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2051947</td>
<td>chr2</td>
<td>PKP4</td>
<td>A G</td>
<td>0.5321</td>
<td>0.4733</td>
<td>0.9884</td>
<td>1.3472</td>
<td>0.0644</td>
<td>3.71E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs12694965</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.532</td>
<td>0.4732</td>
<td>0.9886</td>
<td>1.3474</td>
<td>0.0644</td>
<td>3.66E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10191923</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.5321</td>
<td>0.4735</td>
<td>0.9882</td>
<td>1.3467</td>
<td>0.0644</td>
<td>3.88E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10191934</td>
<td>chr2</td>
<td>PKP4</td>
<td>T G</td>
<td>0.5322</td>
<td>0.4736</td>
<td>0.9877</td>
<td>1.3461</td>
<td>0.0644</td>
<td>3.97E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10191939</td>
<td>chr2</td>
<td>PKP4</td>
<td>A T</td>
<td>0.4679</td>
<td>0.5267</td>
<td>0.9885</td>
<td>0.7423</td>
<td>0.0644</td>
<td>3.72E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chr2_159465312_I</td>
<td>chr2</td>
<td>PKP4</td>
<td>I5 D</td>
<td>0.4498</td>
<td>0.5053</td>
<td>0.9315</td>
<td>0.7371</td>
<td>0.0663</td>
<td>4.28E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3771643</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.532</td>
<td>0.4731</td>
<td>0.9889</td>
<td>1.3483</td>
<td>0.0644</td>
<td>3.46E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs3771647</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.5321</td>
<td>0.4735</td>
<td>0.9893</td>
<td>1.3459</td>
<td>0.0644</td>
<td>3.93E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs7607589</td>
<td>chr2</td>
<td>PKP4</td>
<td>T C</td>
<td>0.4594</td>
<td>0.5159</td>
<td>0.9845</td>
<td>0.7404</td>
<td>0.0645</td>
<td>3.18E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chr2_159476445_D</td>
<td>chr2</td>
<td>PKP4</td>
<td>I13 D</td>
<td>0.5489</td>
<td>0.4908</td>
<td>0.9403</td>
<td>1.3685</td>
<td>0.0661</td>
<td>2.04E-06</td>
<td>IMP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1: Results of the gene-based analysis using MAGMA: Most significant genes (p<5x10^{-4}) in the gene-based analysis and their chromosomal position. Genes in bold font were significant after correction for multiple testing; CHR = chromosome, NSNPS = number of SNPs, NPARAM = number of parameters used in the model, ZSTAT: z-value of the gene, P = gene p-value

<table>
<thead>
<tr>
<th>GENE</th>
<th>CHR</th>
<th>START</th>
<th>STOP</th>
<th>NSNPS</th>
<th>NPARAM</th>
<th>ZSTAT</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKP4</td>
<td>2</td>
<td>159303476</td>
<td>159547941</td>
<td>21</td>
<td>13</td>
<td>4.7924</td>
<td>8.24x10^{-7}</td>
</tr>
<tr>
<td>DYPD</td>
<td>1</td>
<td>97533299</td>
<td>98396615</td>
<td>105</td>
<td>68</td>
<td>4.7162</td>
<td>1.20x10^{-6}</td>
</tr>
<tr>
<td>GRAMD1B</td>
<td>11</td>
<td>123315191</td>
<td>123508478</td>
<td>34</td>
<td>28</td>
<td>3.8856</td>
<td>5.10x10^{-5}</td>
</tr>
<tr>
<td>STX8</td>
<td>17</td>
<td>9143788</td>
<td>9489275</td>
<td>38</td>
<td>33</td>
<td>3.7984</td>
<td>7.28x10^{-5}</td>
</tr>
<tr>
<td>BMP2</td>
<td>20</td>
<td>6738745</td>
<td>6770910</td>
<td>7</td>
<td>6</td>
<td>3.588</td>
<td>1.67x10^{-4}</td>
</tr>
<tr>
<td>TRAF3IP1</td>
<td>2</td>
<td>239219185</td>
<td>239319541</td>
<td>11</td>
<td>8</td>
<td>3.5389</td>
<td>2.01x10^{-4}</td>
</tr>
<tr>
<td>ZP3</td>
<td>7</td>
<td>76016841</td>
<td>76081388</td>
<td>9</td>
<td>7</td>
<td>3.5037</td>
<td>2.29x10^{-4}</td>
</tr>
<tr>
<td>PINX1</td>
<td>8</td>
<td>10612473</td>
<td>10707394</td>
<td>19</td>
<td>11</td>
<td>3.5034</td>
<td>2.30x10^{-4}</td>
</tr>
<tr>
<td>GTF3C4</td>
<td>9</td>
<td>135535728</td>
<td>135575471</td>
<td>4</td>
<td>4</td>
<td>3.4851</td>
<td>2.46x10^{-4}</td>
</tr>
<tr>
<td>DNAH1</td>
<td>3</td>
<td>52340335</td>
<td>5244513</td>
<td>11</td>
<td>8</td>
<td>3.4543</td>
<td>2.76x10^{-4}</td>
</tr>
<tr>
<td>YKT6</td>
<td>7</td>
<td>44230577</td>
<td>44263893</td>
<td>6</td>
<td>3</td>
<td>3.3841</td>
<td>3.57x10^{-4}</td>
</tr>
<tr>
<td>CCSER1</td>
<td>4</td>
<td>91038684</td>
<td>92533370</td>
<td>111</td>
<td>78</td>
<td>3.3804</td>
<td>3.62x10^{-4}</td>
</tr>
<tr>
<td>LRRC59</td>
<td>17</td>
<td>48448594</td>
<td>48484914</td>
<td>8</td>
<td>6</td>
<td>3.3716</td>
<td>3.74x10^{-4}</td>
</tr>
<tr>
<td>TMEM71</td>
<td>8</td>
<td>133712191</td>
<td>133782914</td>
<td>9</td>
<td>8</td>
<td>3.3668</td>
<td>3.80x10^{-4}</td>
</tr>
<tr>
<td>BAP1</td>
<td>3</td>
<td>52425020</td>
<td>52454121</td>
<td>3</td>
<td>3</td>
<td>3.345</td>
<td>4.11x10^{-4}</td>
</tr>
<tr>
<td>AQR</td>
<td>15</td>
<td>35138552</td>
<td>35271995</td>
<td>8</td>
<td>6</td>
<td>3.3299</td>
<td>4.34x10^{-4}</td>
</tr>
<tr>
<td>FGFR1</td>
<td>8</td>
<td>38258656</td>
<td>38336352</td>
<td>12</td>
<td>10</td>
<td>3.3162</td>
<td>4.56x10^{-4}</td>
</tr>
</tbody>
</table>
**Table 2: Results of the gene-set analysis:** Most significant gene-sets (uncorrected $p<0.01$) in the gene-set analysis with i-GSEA4GWAS v2 are listed. Gene-sets in bold font were significant after correction for multiple testing, $P$-value = gene-set $p$-value, FDR = false discovery rate

<table>
<thead>
<tr>
<th>Gene-set Name</th>
<th>Number of genes</th>
<th>$P$-value</th>
<th>FDR $P$-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GO: EXOCYTOSIS</strong></td>
<td>25</td>
<td>0.001</td>
<td>0.019</td>
</tr>
<tr>
<td>GO: RESPONSE TO ORGANIC SUBSTANCE</td>
<td>30</td>
<td>0.002</td>
<td>0.173</td>
</tr>
<tr>
<td>GO: BRAIN DEVELOPMENT</td>
<td>51</td>
<td>0.003</td>
<td>0.888</td>
</tr>
<tr>
<td>GO: HORMONE METABOLIC PROCESS</td>
<td>30</td>
<td>0.003</td>
<td>0.511</td>
</tr>
<tr>
<td>GO: PROTEIN C TERMINUS BINDING</td>
<td>73</td>
<td>0.003</td>
<td>0.536</td>
</tr>
<tr>
<td>GO: LYSOSOME</td>
<td>53</td>
<td>0.007</td>
<td>0.785</td>
</tr>
<tr>
<td>GO: LYTIC VACUOLE</td>
<td>53</td>
<td>0.007</td>
<td>0.785</td>
</tr>
<tr>
<td>GO: MULTI ORGANISM PROCESS</td>
<td>143</td>
<td>0.007</td>
<td>0.920</td>
</tr>
</tbody>
</table>